ac3174 and Body-Weight

ac3174 has been researched along with Body-Weight* in 1 studies

Other Studies

1 other study(ies) available for ac3174 and Body-Weight

ArticleYear
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    American journal of physiology. Gastrointestinal and liver physiology, 2012, Apr-15, Volume: 302, Issue:8

    These preclinical studies aimed to 1) increase our understanding the dietary induction of nonalcoholic steatohepatitis (NASH), and, 2) further explore the utility and mechanisms of glucagon-like peptide-1 receptor (GLP-1R) agonism in NASH. We compared the effects of a high trans-fat (HTF) or high lard fat (HLF) diet on key facets of nonalcoholic fatty liver disease (NAFLD)/NASH in Lep(ob)/Lep(ob) and C57BL6J (B6) mice. Although HLF-fed mice experienced overall greater gains in weight and adiposity, the addition of trans-fat better mirrored pathophysiological features of NASH (e.g., hepatomegaly, hepatic lipid, and fibrosis). Administration of AC3174, an exenatide analog, and GLP-1R agonist to Lep(ob)/Lep(ob) and B6 ameliorated hepatic endpoints in both dietary models. Next, we assessed whether AC3174-mediated improvements in diet-induced NASH were solely due to weight loss in HTF-fed mice. AC3174-treatment significantly reduced body weight (8.3%), liver mass (14.2%), liver lipid (12.9%), plasma alanine aminotransferase, and triglycerides, whereas a calorie-restricted, weight-matched group demonstrated only modest nonsignificant reductions in liver mass (9%) and liver lipid (5.1%) relative to controls. Treatment of GLP-1R-deficient (GLP-1RKO) mice with AC3174 had no effect on body weight, adiposity, liver or plasma indices pointing to the GLP-1R-dependence of AC3174's effects. Interestingly, the role of endogenous GLP-1Rs in NASH merits further exploration as the GLP-1RKO model was protected from the deleterious hepatic effects of HTF. Our pharmacological data further support the clinical evaluation of the utility of GLP-1R agonists for treatment of NASH.

    Topics: Animals; Body Composition; Body Weight; Diet; Diet, Fat-Restricted; Diet, High-Fat; Endpoint Determination; Fatty Liver; Gene Expression; Glucagon-Like Peptide-1 Receptor; Hormones; Leptin; Lipids; Liver; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Non-alcoholic Fatty Liver Disease; Peptides; Receptors, Glucagon; Trans Fatty Acids; Weight Loss

2012